Plus, news about TScan Therapeutics:
Histogen files for Chapter 11 bankruptcy: The biotech, which stopped work in September, filed a petition with the US Bankruptcy Court for the Southern District of California. Its next steps include confirming a plan of liquidation to distribute value to stakeholders. — Ayisha Sharma
Barinthus Bio touts Ph1b/2 HPV data: The company’s immunotherapy candidate, VTP-200, met the primary safety endpoint in a trial of 108 women with high-risk HPV-associated low-grade cervical lesions. The group with the highest treatment dose achieved a 60% high-risk HPV clearance rate at 12 months versus a 33% clearance rate for placebo. — Ayisha Sharma
TScan Therapeutics closed its $150 million offering. — Jaimy Lee